Award Data

Project Summary Sanfilippo disease (mucopolysaccharidosis type III; MPS III) is a devastating neurodegenerative lysosomal storage disorder of childhood whose pathologic features are neurologic: slowing of development, severe behavioral problems, progressive cognitive decline, dementia, and decline in motor skills leading to immobility, unresponsiveness, and death. We have focused on MPS IIID cause ...

Improved head and hearing protection is required for aircraft maintainers working on a carrier flight deck during launch and recovery operations. Legacy Flight Deck Cranials are inadequate in many aspects including hearing protection, impact protection, cleaning, comfort, and compatibility with night vision devices (NVDs) and with chemical, biological, and radiological (CBR) equipment. In this p ...

Synchrotron light sources and X-ray free electron lasers are now generating shorter pulses with more intense light than ever before possible. The capabilities of these new sources grant unprecedented access into the workings of the natural world. X-ray detectors, as they currently stand, cannot accommodate the large dynamic range of collected x-rays in modern scattering experiments. This capabilit ...

Nanocerox proposes to use our custom formulated, high purity yttrium aluminum garnet (YAG) nanopowder for the production of YAG windows 6” by 12” by 10 mm thick with theoretical transmission from visible to 5µm wavelengths to demonstrate their utility in IR transparent material applications. YAG is a high strength ceramic which, with proper processing, can achieve our phase II optical goals ...

Project Summary Mucopolysaccharidosis type IMPS Iis an autosomal recessive storage disease caused by the absence ofL iduronidaseIDUAresulting in systemic accumulation of glycosaminoglycanGAGstorage materialshepatosplenomegalyskeletal dysplasiascardiopulmonary obstructionprogressive neurologic impairment and death by ageMPS I is currently treated by enzyme replacement therapy and by allogeneic hema ...

From HIV to metastatic cancer, state-of-the-art therapeutics are static biological or pharmaceutical compounds—whose efficacy is inevitably lost once their evolving disease targets sufficiently mutate. We engineered the first adaptive therapeutics designed to co-adapt with adapting disease agents—to provide ‘resistance-proof’ disease control. Known as Therapeutic Interfering Particles (‘ ...

DESCRIPTION (provided by applicant): MedArray has successfully developed under SBIR Phase I and II, a novel silicone membrane hollow fiber for use in blood oxygenators. Our patented silicone hollow fiber has great commercial potential for use in long term extracorporeal membrane oxygenation (ECMO) as well as routine cardiopulmonary bypass. Because ECMO can last more than 1 day, dense rather than ...

DESCRIPTION (provided by applicant): Currently there exists no technology for routine measurement of cardiac output (CO) in neonates (0.4-2.5Kg) and low weight pediatric (2.5Kg+) patients in the intensive care unit (ICU). Accurate measurement of CO would a llow for better assessment of therapies and thereby improve patient health care. Conventional methods used with adults for routine CO measureme ...

DESCRIPTION (provided by applicant): We propose to configure a DNA-based assay to detect mutations in the gene related to cystic fibrosis (CF), encoding the cystic fibrosis transmembrane conductance regulator protein (CFTR). The assay will have an extende

Project Summary. PreCyte is developing the Indicator Cell Assay Platform (iCAP) as a broadly applicable and inexpensive blood-based assay that can be used for the early detection of disease, disease stage stratification, prognosis and predicting response to therapy for a variety of diseases. The iCAP uses cultured, standardized cells as biosensors, capitalizing on the ability of cells to respond t ...